Stanford University (Stanford) psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Stanford University is listed with 6 registered studies counted here, in Stanford, United States. By compound: 1 psilocybin, 4 ketamine and 1 ibogaine. By registry status: 1 recruiting, 1 not yet recruiting, 2 active, not recruiting and 2 completed. By phase: 1 phase 1, 3 phase 2, 1 phase 3 and 1 not reported. Reported start years run from 2016 (earliest) to 2026 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 6 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 1 |
| Ketamine | 4 |
| Ibogaine | 1 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 1 | 17% |
| Not yet recruiting | 1 | 17% |
| Active, not recruiting | 2 | 33% |
| Completed | 2 | 33% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 1 | 1 | 17% |
| Phase 2 | 3 | 50% |
| Phase 3 | 1 | 17% |
| Not reported | 1 | 17% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Anesthesia-Masked Psilocybin Therapy for Major Depression | NCT07479550 | Not yet recruiting | Phase 2 | 2026-07-01 | Psilocybin |
| Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2) | NCT05940324 | Recruiting | Phase 2 | 2024-02-24 | Ketamine |
| Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure | NCT04313712 | Active, not recruiting | Not reported | 2021-11-15 | Ibogaine |
| Opiate Suicide Study in Patients With Major Depression | NCT04116528 | Active, not recruiting | Phase 3 | 2020-08-01 | Ketamine |
| Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD) | NCT02911597 | Completed | Phase 1 | 2016-09-01 | Ketamine |
| Understanding How Ketamine Brings About Rapid Improvement in OCD | NCT02624596 | Completed | Phase 2 | 2016-06-01 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.